EPHB1/2/3 Blocking Peptide

EPHB1; ELK; EPHT2; HEK6; NET; Ephrin type-B receptor 1; ELK; EPH tyrosine kinase 2; EPH-like kinase 6; EK6; hEK6; Neuronally-expressed EPH-related tyrosine kinase; NET; Tyrosine-protein kinase receptor EPH-2; EPHB2; DRT; EPHT3; EPTH3; ERK; HEK5; TYRO5; Ephrin type-B receptor 2; Developmentally-regulated Eph-related tyrosine kinase; ELK-related tyrosine kinase; EPH tyrosine kinase 3; EPH-like kinase 5; EK5; hEK5; Renal carcinoma antigen NY-REN-47; Tyrosine-protein kinase TYRO5; Tyrosine-protein kinase receptor EPH-3; EPHB3; ETK2; HEK2; TYRO6; Ephrin type-B receptor 3; EPH-like tyrosine kinase 2; EPH-like kinase 2; Embryonic kinase 2; EK2; hEK2; Tyrosine-protein kinase TYRO6

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4°C for overnight or at room temperature for 2 hours.